0.69
+0.0534(+8.33%)
Currency In USD
| Previous Close | 0.64 |
| Open | 0.66 |
| Day High | 0.78 |
| Day Low | 0.64 |
| 52-Week High | 34.92 |
| 52-Week Low | 0.61 |
| Volume | 313,012 |
| Average Volume | 1.46M |
| Market Cap | 2.36M |
| PE | -0.04 |
| EPS | -18.16 |
| Moving Average 50 Days | 1.11 |
| Moving Average 200 Days | 3.37 |
| Change | 0.05 |
If you invested $1000 in AIM ImmunoTech Inc. (AIM) 10 years ago, it would be worth $8.22 as of March 07, 2026 at a share price of $0.694. Whereas If you bought $1000 worth of AIM ImmunoTech Inc. (AIM) shares 5 years ago, it would be worth $345.47 as of March 07, 2026 at a share price of $0.694.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
AIM ImmunoTech Announces Closing of its Rights Offering
GlobeNewswire Inc.
5 hours ago
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod),
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
GlobeNewswire Inc.
Mar 04, 2026 2:00 PM GMT
OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod),
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
GlobeNewswire Inc.
Mar 02, 2026 2:00 PM GMT
OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM’s anticipated Phase 3